EFFECT OF GUSELKUMAB ADMINISTERED EVERY 8 WEEKS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS PERSISTS BETWEEN CONSECUTIVE DOSES AND IS DURABLE: POST HOC ANALYSIS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED STUDY

被引：0

作者：

Mease, P. J. ^{[1
,2
]}

Baraliakos, X. ^{[3
]}

Chandran, V. ^{[4
,5
]}

Soriano, E. ^{[6
]}

Nash, P. ^{[7
,8
]}

Deodhar, A. ^{[9
]}

Rampakakis, E. ^{[10
,11
]}

Shiff, N. ^{[12
,13
]}

Chakravarty, S. D. ^{[14
,15
]}

Shawi, M. ^{[16
]}

Merola, J. F. ^{[17
,18
]}

Mcinnes, I. ^{[19
]}

机构：

[1] Providence St Joseph Hlth, Swedish Med Ctr, Seattle, WA USA

[2] Univ Washington, Rheumatol Res, Seattle, WA 98195 USA

[3] Ruhr Univ Bochum, Rheumazentrum Ruhrgebiet, Claudiusstr, Germany

[4] Univ Toronto, Toronto, ON, Canada

[5] Schroeder Arthrit Inst, Dept Med, Div Rheumatol, Toronto, ON, Canada

[6] Hosp Italiano Buenos Aires, Rheumatol, Buenos Aires, DF, Argentina

[7] Griffith Univ, Maroochydore, Australia

[8] Univ Queensland, Rheumatol Res Unit, Maroochydore, Australia

[9] Oregon Hlth & Sci Univ, Div Arthrit & Rheumat Dis, Portand, OR USA

[10] McGill Univ, Dept Pediat, Montreal, PQ, Canada

[11] JSS Med Res Inc, Sci Affairs, Montreal, PQ, Canada

[12] Janssen Sci Affairs LLC, Immunol, Horsham, PA USA

[13] Univ Saskatchewan, Community Hlth & Epidemiol, Saskatoon, SK, Canada

[14] Janssen Sci Affairs LLC, Immunol, Horsham, PA USA

[15] Drexel Univ, Coll Med, Div Rheumatol, Philadelphia, PA 19104 USA

[16] Janssen Pharmaceut Co Johnson & Johnson, Immunol Global Med Affairs, Horsham, PA USA

[17] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA

[18] Harvard Med Sch, Div Rheumatol & Immunol, Boston, MA 02115 USA

[19] Univ Glasgow, Coll Med Vet & Life Sci, Inst Infect Immun & Inflammat, Glasgow, Lanark, Scotland

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2023年 / 82卷

关键词：

Clinical trials; Psoriatic arthritis; Outcome measures;

D O I：

10.1136/annrheumdis-2023-eular.642

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

AB1108

引用

页码：1782 / 1783

页数：2

共 3 条

[1] Long-Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin-23, Through Two Years: Results From a Phase III, Randomized, Double-Blind, Placebo-Controlled Study Conducted in Biologic-Naive Patients With Active Psoriatic Arthritis [J].

McInnes, Iain B. ;

Rahman, Proton ;

Gottlieb, Alice B. ;

Hsia, Elizabeth C. ;

Kollmeier, Alexa P. ;

Xu, Xie L. ;

Jiang, Yusang ;

Sheng, Shihong ;

Shawi, May ;

Chakravarty, Soumya D. ;

van der Heijde, Desiree ;

Mease, Philip J. .

ARTHRITIS & RHEUMATOLOGY, 2022, 74 (03) :475-485

[2]

Ritchlin C, 2022, ARTHRITIS RHEUMAT S9, V74

[3] Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies [J].

Ritchlin, Christopher T. ;

Mease, Philip J. ;

Boehncke, Wolf-Henning ;

Tesser, John ;

Schiopu, Elena ;

Chakravarty, Soumya D. ;

Kollmeier, Alexa P. ;

Xu, Xie L. ;

Shawi, May ;

Jiang, Yusang ;

Sheng, Shihong ;

Wang, Yanli ;

Xu, Stephen ;

Merola, Joseph F. ;

McInnes, Iain B. ;

Deodhar, Atul .

RMD OPEN, 2022, 8 (01)

← 1 →